مباشر

Clinical OMICsMayo Clinic’s REDMOD AI Doubles Early Detection Sensitivity in Pancreatic Cancer FierceBiotechIpsen scuttles liver disease candidates from $952M Albireo acquisition AmgenBiopharma Manufacturing Expands in the U.S.: Amgen, Lilly Double Down on Capacity and Next-Gen Production - BioPharm International Endpoints NewsAmgen, AbbVie say IRA negotiations impacted Q1 sales Clinical OMICsAt-Home Blood Test Screens for Early Dementia Clinical OMICsGlioblastoma: Testosterone Supplements Linked to 38% Lower Risk of Death Endpoints NewsLilly plans new $4.5B manufacturing investment in Indiana Endpoints NewsBeOne culls five cancer programs and an autoimmune Phase 2 Endpoints NewsLonza looks to ride ADC wave with upcoming factory, workforce expansion FierceBiotechBipartisan PRIMATE Act aims to ban monkey imports to US Clinical OMICsEarly Glucagon Elevation Linked to MASLD in Type 2 Diabetes Clinical OMICsEpigenetic Markers Link Early-Onset Colon and Rectal Cancer to Specific Pesticide

Clinical OMICs ٦ مايو ٢٠٢٦

Mayo Clinic’s REDMOD AI Doubles Early Detection Sensitivity in Pancreatic Cancer

REDMOD identified 73% of those prediagnostic cancers at a median of about 16 months before diagnosis, nearly double the detection rate of specialists reviewing...

REDMOD identified 73% of those prediagnostic cancers at a median of about 16 months before diagnosis, nearly double the detection rate of specialists reviewing the same scans without AI assistance. The post Mayo Clinic’s REDMOD AI Doubles Early Detection Sensitivity in Pancreatic Cancer appeared first on Inside Precision Medicine .